Neurotech S.A. (Paris, France) has named Ted Danse as new President and Chief Executive Officer. Danse has a record of more than 25 years in life science industries. He served as President and CEO of the public US ophthalmic pharmaceutical company ISTA Pharmaceuticals Inc. and was Director on the boards of Quest Vision Technologies, Inc. and Vision Solutions Technologies, Inc. Other stations of his carreer include business development roles at Coopervision, Bausch & Lomb, Schering-Plough and Allergan.



Leverkusen – German dermatology specialist Biofrontera AG’s experimental treatment for the skin disorder actinic keratosis has outperformed the current treatment standard, Metvix. According to the results of a multi-centre phase...



Nice – French NicOx SA has announced that it will be further increasing its capital with the aim of expanding the supply of its lead candidate Naproxcinod, and to implement a sales team in the US market, for which the company is...

BeNeLux, France, UK, PortugalFrance


Lissabon/Leicester/Oeiras/Strasbourg/Utrecht - A set of genes that is known to control many aspects of embryonic development is also involved in determining the number of vertebrae in the spine, according to the results of new...

Germany, FranceFrance


Bethesda/Munich/Paris - Micromet Inc. partnered with sanofi-aventis Group to develop one of the biotech's bispecific T cell engager (BiTE) antibodies for cancer. The Paris-based pharma will pay €8 million up front, and Micromet...



Paris - French President Nicolas Sarkozy at the fourth session of the Strategic Council for Health Industries has announced an investment of €139 million ($206.5 million ) for the establishment of a biotechnology fund. The...

Denmark, Germany, France, UKFrance


Strasbourg – By studying mosquito genomes, researchers have identified differences in the expression of a single gene that determines whether or not a mosquito can transmit malaria parasites. This discovery provides a genetic...



Grenoble – French specialists in high content screening (HCS), Cytoo SA, have secured EUR3m in a second funding round led by its new investor Auriga Partners. The one year old company said it will use the money to expand its...



Paris – Nearly half of all French universities are aiming to raise private money by setting up new foundations. By January of 2010, more than 60 academic institutions will be declared autonomous and given the freedom to build...



Paris – Two US companies with French roots have listed on the Euronext without raising money. Cardiovascular, neurology and metabolic company Quantum Genomics Corp. registered 39.3 million shares for trading at EUR1.04. The...

Editorial, FranceFrance


The present crisis marks a major breaking point in the growth model and the financial fundamentals upon which mature economies are based. It has raised important issues concerning value creation, innovation and – above all – the...

Displaying results 91 to 100 out of 268

< Previous 91-100 Next >

© 2007-2015 BIOCOM


LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week


Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...


All Events



BioVaria 2015

Stock list

All quotes


  • WILEX4.84 EUR34.82%
  • FORMYCON31.25 EUR11.61%
  • PAION2.76 EUR6.98%


  • MEDIGENE12.41 EUR-3.42%
  • SANTHERA96.75 CHF-2.12%
  • MOLOGEN5.01 EUR-1.18%


  • WILEX4.84 EUR63.5%
  • FORMYCON31.25 EUR35.0%
  • CO.DON3.35 EUR29.8%


  • CYTOS1.08 CHF-22.9%
  • BIOTEST78.40 EUR-18.9%
  • THERAMETRICS0.07 CHF-12.5%


  • SANTHERA96.75 CHF2368.1%
  • CYTOS1.08 CHF671.4%
  • WILEX4.84 EUR469.4%


  • MOLOGEN5.01 EUR-55.5%
  • BIOFRONTERA2.40 EUR-26.8%
  • THERAMETRICS0.07 CHF-22.2%

No liability assumed, Date: 27.04.2015

Current issue

All issues